Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, January 5, 2012 – Astellas Pharma Inc. (Tokyo:4503, “Astellas”) announces that it will halt exports of Gaster-D 20mg tablets to Korea for a period of three months in accordance with a...
Read more about Temporary Halt of Gaster-D 20mg Tablet Exports to Korea
SAN DIEGO, Calif. and Deerfield, Ill., December 21, 2011 — Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous...
Tokyo, December 9, 2011 - Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today announced that the Ireland Japan Chamber of Commerce (IJCC, http://www.ijcc.jp/) presented it with a business...
Tokyo, November 11, 2011 - Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today announced the receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating that it accepted...
Read more about Receipt of Filing Communication Letter from U.S. FDA Regarding Mirabegron (YM178)
Astellas Pharma Inc. (Headquarters, Tokyo; President & CEO, Yoshihiko Hatanaka) today announced that the administration of the recombinant influenza HA vaccine (H5N1) ASP7373 (former code:...
Follow us
